Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders

https://doi.org/10.1016/0014-2999(95)00762-8Get rights and content

Abstract

The present studies assessed the levels of [125I][Sar1,Ile8]angiotensin II-labelled angiotensin AT1 and AT2 receptor recognition sites in homogenates of various brain areas (including caudate nucleus, putamen, substantia nigra, hippocampus, frontal cortex, temporal cortex and cerebellum) from patients with clinically diagnosed Parkinson's disease, Huntington's disease and Alzheimer's disease and those from age-, sex- and post-mortem delay-matched neurologically and psychiatrically normal patients. Radiolabelled angiotensin AT1 receptor recognition site levels were significantly decreased by approximately 70%, 70% and 90% in the caudate nucleus, putamen and substantia nigra, respectively, from patients with Parkinson's disease relative to matched controls. Furthermore, radiolabelled angiotensin AT2 receptor levels were decreased by some 60% in the caudate nucleus of patients with Parkinson's disease relative to control patients. In brain tissue homogenates from patients with Huntington's disease, the angiotensin AT1 receptor recognition site levels were decreased by approximately 30% in putamen relative to the control patients whilst angiotensin AT2 receptor levels were increased by some 90% in the caudate nucleus relative to the control patients. In brain tissue homogenates from patients with Alzheimer disease, the angiotensin AT2 receptor recognition site levels were significantly increased by approximately 200% in the temporal cortex relative to the control patients. The present results indicate that the reduction of angiotensin AT1 and/or AT2 receptor recognition site levels in the caudate nucleus, putamen and substantia nigra correlates with the principal neuropathology associated with Parkinson's disease and as such indicates that at least a significant population of angiotensin AT1 and AT2 receptors are located on the human dopaminergic nigrostriatal pathway. In addition, the marked increase in the levels of angiotensin AT2 receptor recognition sites in temporal cortex from patients with Alzheimer's disease correlates with some other markers associated with the renin-angiotensin system previously investigated in tissue from patients with this neurological disease.

References (37)

  • G.P. Reynolds et al.

    Neurochemical abnormalities in Huntington's disease: neurotoxic mechanisms and neurotransmitter changes

    J. Neurologi. Sci.

    (1992)
  • M. Schinke et al.

    Characterization of rat intestinal angiotensin II receptors

    Eur. J. Pharmacol.

    (1991)
  • G. Simonnet et al.

    Stimulating effect of angiotensin II on the spontaneous release of newly synthesized [3H]dopamine in rat striatal slices

    Neurosci. Lett.

    (1979)
  • P.B.M.W.M. Timmermans et al.

    Nonpeptide angiotensin II receptor antagonists

    Trends Pharmacol. Sci.

    (1991)
  • A.M. Allen et al.

    Angiotensin II receptor binding associated with nigro-striatal dopaminergic neurones in human basal ganglia

    Ann. Neurol.

    (1992)
  • A. Arregui et al.

    Alterations in postmortem brain angiotensin-converting enzyme activity and some neuropeptides in Huntington's disease

  • A. Arregui et al.

    Angiotensin converting enzyme in Alzheimer's disease: increased activity in caudate nucleus and cortical areas

    J. Neurochem.

    (1982)
  • N.M. Barnes et al.

    Anxiolytic-like action of DuP753, a potent and selective non-peptide angiotensin II receptor antagonist

    NeuroReport

    (1990)
  • Cited by (98)

    • ACE2/angiotensin-(1–7)/mas receptor axis in the central nervous system

      2023, Angiotensin: From the Kidney to Coronavirus
    • Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives

      2018, Journal of Molecular Graphics and Modelling
      Citation Excerpt :

      The effects of AT1 antagonists are not limited to cardiovascular diseases. It is reported that AT1 receptor blockers may be used as potential anti-cancer agents − due to the inhibition of cell proliferation stimulated by A-II − and also can be used against Alzheimer’s disease [7,8]. Therefore, AT1 receptors and the A-II biosynthesis mechanisms are targets for the development of new synthetic drugs and therapeutic treatment of various cardiovascular and such diseases.

    View all citing articles on Scopus
    View full text